Hey Ministry of Health Reported on Wednesday night (26) that there are seven confirmed cases of the so-called B.1.617, the Indian version of the new Coronavirus in Brazil. There are six cases in Sao Luiz, Maranho, and one in Campos dos Goytacze in Rio de Janeiro.
In addition, according to the folder, three other suspected cases are being monitored in Minas Gerais and Para, awaiting the completion of genetic sequencing.
“Cases in DF and CE left for new version”, informed the ministry G1.
The case that the Ministry has associated with Campos dos Goytacz is that Passenger from India to Kumbika Airport in Guarulhos, And was diagnosed with the Indian version of Coronavirus on Wednesday.
According to a report published on Wednesday by the World Health Organization (WHO), the version has already been officially found in 49 countries and 4 regions. According to the WHO document, B.1.617 is more contagious than the initial with the British version, but it is still investigated if it relates to more severe cases of Covid-19 and if it increases the risk of re-infection. is.
VIDEO: Discover 4 types of new coronaviruses
The Indian version was first registered in India in October last year. With the explosion of affairs in the country and its outbreak in the United Kingdom, it began to worry the world. This occurred, according to the transitionists, since the variant became possibly more permeable after encountering mutations since its discovery.
One type is the result of genetic modifications that the virus undergoes during its replication process. There can be many forms of the same virus. The more the virus spreads – the more it spreads from one person to another – the more it repeats, and the greater the likelihood of changes in its genetic material.
Although it was seen last year, it was only on 10 May The World Health Organization (WHO) classified B.1.617 as a “global concern”.
“There is some information available that indicates marked transmissibility,” WHO technical leader Maria van Kerkov said during an announcement.
The three versions identified so far of this version are: B.1.617.1, B.1.617.2 and B.1.617.3. All were first discovered in India.
The variants are believed to spread rapidly, but scientists still cannot say whether they are more lethal and have greater transmission capacity.
According to the WHO Weekly Bulletin, the “attack rate” of B1.617.2, a sub-lineage of the Indian version, appears to be higher than the British version (B.1.1.7). The document states, “New evidence is coming out that the attack rate for the variant B.1.617.2 reported between 29 March and 28 April 2021 in the UK was higher than that of B.1.1.7. ”
Subline B.1.617.2 also reduces the effectiveness of Pfizer and Oxford / AstraZeneca vaccines, but according to one preliminary study the antibodies are still “highly effective”.
Explosion of cases and deaths by Kovid-19 in India: Understand in 5 points
Pfizer / Bioentech and AstraZeneca / Oxford vaccines are vaccine “Highly effective” against the sub-lineage B.1.617.2 of the Indian version, According to a preliminary study released on Saturday (22).
Completion of Public Health Agency in England. The article has not yet been reviewed by other scientists and has not been published in a scientific journal.
Research conducted between 5 April and 16 May measured how successful each vaccine was in reducing the symptomatic cases of Kovid-19 caused by B1.1.7 (British version) and B1.617.2.
The main findings were:
- The Pfizer / Bioentech vaccine was 88% effective against symptomatic cases of Kovid-19 caused by the Indian version (B.1.617.2) two weeks after the second dose. With respect to the British version (B.1.1.7), the effectiveness was slightly higher: 93%.
- The Oxford / AstraZeneca vaccine was 60% effective against symptomatic cases of Kovid-19 caused by the Indian version (B.1.617.2) after the second dose. With respect to the British version (B.1.1.7), the effectiveness was also slightly higher: 66%.
- Both vaccines were 33% effective against symptomatic cases of Kovid-19 due to the Indian version (B.1.617.2) after the first dose. With respect to the British version (B.1.1.7), the effectiveness of both was 50%.